GLENMARK PHARMACEUTICALS SHARE PRICE

Glenmark Pharmaceuticals Ltd. is an Indian multinational pharmaceutical company manufacturing generic drugs and active pharmaceutical ingredients. It was founded in 1977 by Gracias Saldanha. The company’s headquarters are in Mumbai. For FY 2021-2022, Glenmark Pharmaceuticals Ltd.’s total revenue was Rs 12,471.58 crore, up 13.44% from Rs 10,994.15 crore in the previous financial year 2020-2021. On 8 August 2022, the company’s market capitalisation stood at Rs HYPERLINK "https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/glenmarkpharma/GP08" 10,483 crore. 

The company is listed on the Bombay Stock Exchange with the code 532296 and on the National Stock Exchange with the code GLENMARK.  

Glenmark Pharmaceuticals Ltd. is involved in developing and marketing branded and generic formulations. The company’s innovative drug discovery effort focuses on the areas of metabolic disorders (obesity, diabetes, etc.), inflammation (rheumatoid arthritis, asthma/COPD, etc.), and pain (inflammatory pain and neuropathic pain). It manufactures formulations across therapeutic areas of respiratory, diabetes, cardiac, dermatology, gynaecology, anti-infective, oncology, and CNS.  

The company’s shareholding pattern on 30 June 2022 showed a promoter stake of 46.65%, foreign institutional investor stake of 24.23%, domestic institutional investor stake of 10.49%, and public stake of 18.62%. The Saldanha Family Trust is the leading promoter with a 45.45% share. During the quarter ended June 2022, mutual funds decreased holdings from 6.18% to 5.81%, with the number of mutual fund schemes reducing from 21 to 19.  

Mr Glenn Saldanha is the company’s chairman and managing director. The top management comprises Mr D R Mehta, Mr Sridhar Gorthi, Mr Dipankar Bhattacharjee, Mr Rajesh V Desai, Mrs Cherylann Pinto, Mrs B E Saldanha, Mr Bernard Munos, Dr Brian W Tempest, Mr V S Mani, and Ms Saira Ramasastry. The auditors are Suresh Surana & Associates LLP and Walker, Chandiok & Co.LLP.  

On 8 August 2022, Glenmark Pharmaceuticals Ltd.’s BSE share price was trending at Rs 372.45, while the NSE share price was trending at Rs 372.50. The 52-week high for Glenmark Pharmaceuticals Ltd.’s share price was Rs 597.90, and the 52-week low for the company’s share price was Rs 348.50.  

The company’s peers include Sun Pharmaceutical Industries Ltd., Divis Laboratories Ltd., Cipla Ltd., and Dr Reddys Laboratories Ltd. 

Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Glenmark Pharmaceuticals Ltd. is an Indian multinational pharmaceutical company manufacturing generic drugs and active pharmaceutical ingredients. It was founded in 1977 by Gracias Saldanha. The company’s headquarters are in Mumbai. For FY 2021-2022, Glenmark Pharmaceuticals Ltd.’s total revenue was Rs 12,471.58 crore, up 13.44% from Rs 10,994.15 crore in the previous financial year 2020-2021. On 8 August 2022, the company’s market capitalisation stood at Rs HYPERLINK "https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/glenmarkpharma/GP08" 10,483 crore. 

The company is listed on the Bombay Stock Exchange with the code 532296 and on the National Stock Exchange with the code GLENMARK.  

Glenmark Pharmaceuticals Ltd. is involved in developing and marketing branded and generic formulations. The company’s innovative drug discovery effort focuses on the areas of metabolic disorders (obesity, diabetes, etc.), inflammation (rheumatoid arthritis, asthma/COPD, etc.), and pain (inflammatory pain and neuropathic pain). It manufactures formulations across therapeutic areas of respiratory, diabetes, cardiac, dermatology, gynaecology, anti-infective, oncology, and CNS.  

The company’s shareholding pattern on 30 June 2022 showed a promoter stake of 46.65%, foreign institutional investor stake of 24.23%, domestic institutional investor stake of 10.49%, and public stake of 18.62%. The Saldanha Family Trust is the leading promoter with a 45.45% share. During the quarter ended June 2022, mutual funds decreased holdings from 6.18% to 5.81%, with the number of mutual fund schemes reducing from 21 to 19.  

Mr Glenn Saldanha is the company’s chairman and managing director. The top management comprises Mr D R Mehta, Mr Sridhar Gorthi, Mr Dipankar Bhattacharjee, Mr Rajesh V Desai, Mrs Cherylann Pinto, Mrs B E Saldanha, Mr Bernard Munos, Dr Brian W Tempest, Mr V S Mani, and Ms Saira Ramasastry. The auditors are Suresh Surana & Associates LLP and Walker, Chandiok & Co.LLP.  

On 8 August 2022, Glenmark Pharmaceuticals Ltd.’s BSE share price was trending at Rs 372.45, while the NSE share price was trending at Rs 372.50. The 52-week high for Glenmark Pharmaceuticals Ltd.’s share price was Rs 597.90, and the 52-week low for the company’s share price was Rs 348.50.  

The company’s peers include Sun Pharmaceutical Industries Ltd., Divis Laboratories Ltd., Cipla Ltd., and Dr Reddys Laboratories Ltd. 

Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.